Publications by authors named "Jess Hoag"
Article Synopsis
- - The RSClinN+ tool was developed to better predict recurrence risk and the benefits of chemotherapy specifically for patients with HR+/HER2-negative, lymph node-positive breast cancer, by incorporating both the Oncotype DX score and other clinical factors like tumor size and age.
- - Analysis of data from over 5,000 patients revealed that RSClinN+ offered significantly improved prognostic accuracy compared to using the Oncotype DX score alone or clinicopathological models, especially for premenopausal and postmenopausal women.
- - Validation of RSClinN+ showed that it effectively estimates prognosis and potential chemotherapy benefits, making it a valuable personalized tool for clinicians in managing breast cancer treatment decisions.
Article Synopsis
- The 21-gene recurrence score (RS) test, called Oncotype DX, helps decide if breast cancer patients need chemotherapy.
- Researchers studied over 10,000 women to see how well the RS works with other information like tumor size and patient age to predict cancer recurrence after treatment.
- They found that combining the RS with other factors gives much better predictions about whether the cancer will come back, especially between 5 to 10 years after diagnosis.
Colorectal cancer (CRC) is a common cancer in younger adults. In patients undergoing liver resection with RAS-altered CRCs, there is evidence suggesting younger patients have worse outcomes than older patients. To explain this pattern, differences in associations between RAS status and other cancer-related biomarkers in tumors from younger versus older patients with CRC were evaluated in a cohort of 925 patients with CRC, 277 (30.
View Article and Find Full Text PDFBackground: HER2 immunohistochemistry (IHC) reproducibility is suboptimal for HER-low cases (IHC 1+ or 2+).
Methods: The Yale cohort included 214 stages I-II estrogen receptor positive breast cancers with IHC scores 0, 1+, and 2+ and routine Oncotype DX Recurrence Score (RS) results. The Exact Sciences (ES) cohort included 9 57 624 patients who had an Oncotype DX RS assay that assigns HER2-negative, equivocal, or positive status based on HER2 mRNA levels.